Genmab at 3-year high after blood cancer drug combination study results

AbbVie

06/10/2026 08:18

        ** Shares in Genmab GMAB.CO rise around 8% to their highest in three years, hitting top of STOXX 600 .STOXX index
** Genmab and AbbVie ABBV.N said on Monday their blood cancer drug combination cut risk of progression and death in late-stage study
** The companies said the combination reduced the risk of disease progression or death in newly diagnosed patients compared with R-CHOP alone by 51%, which analysts at Jefferies called "impressive"
** The broker adds this data "comfortably clears the bar for success", beating investors' expectations of around 40%
** The data establishes the combination as a potential new standard of care, unlocking peak potential of over $3 billion, says TD Cowen
     

(Reporting by Vera Dvorakova)
((vera.dvorakova@thomsonreuters.com))